Chronic pain: Reducing costs through early implementation of adherence testing and recognition of opioid misuse

Postgraduate Medicine

Volumn 123, Issue 6, 2011, Pages 132-139

  McCarberg, Bill H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic pain; Opioid adherence; Reducing costs

Indexed keywords

ACETYLSALICYLIC ACID PLUS OXYCODONE PLUS OXYCODONE TEREPHTHALATE; CARISOPRODOL; CODEINE; HYDROCODONE BITARTRATE PLUS IBUPROFEN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; ILLICIT DRUG; MORPHINE SULFATE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYCODONE PLUS PARACETAMOL; PERCOCET; TYLOX;

ABSENTEEISM; ARTICLE; CHRONIC PAIN; COMORBIDITY; COST BENEFIT ANALYSIS; COST CONTROL; DEPRESSION; HEALTH CARE COST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITALIZATION; HUMAN; LOW BACK PAIN; MASS FRAGMENTOGRAPHY; MIGRAINE; NARCOTIC DEPENDENCE; NEUROPATHIC PAIN; OSTEOPOROSIS; PATIENT COMPLIANCE; POINT OF CARE TESTING; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; UNEMPLOYMENT; UNITED STATES; URINALYSIS; URINE DRUG TEST; WORK DISABILITY;

ANALGESICS, OPIOID; CHRONIC PAIN; COST SAVINGS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MEDICATION ADHERENCE; OPIOID-RELATED DISORDERS; PAIN MANAGEMENT; POINT-OF-CARE SYSTEMS; SUBSTANCE ABUSE DETECTION; URINALYSIS;

EID: 82155179164     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.11.2503     Document Type: Article

References (44)

1. McCarberg BH, Billington R. Consequences of neuropathic pain: quality-of-life issues and associated costs. Am J Manag Care. 2006; 12(suppl 9):S263-S268.
2. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and American Pain Society. Clin J Pain. 1997;13(1):6-8.
3. National Institutes of Health. New directions in pain research: I. PA-98-102; September 4, 1998. http://grants.nih.gov/grants/guide/pa-files/PA-98-102.html. Accessed November 18, 2010.
4. Kim Le T, Montejano L, Johnston J, et al. Comparison of healthcare expenditures associated with different chronic pain conditions. 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3, 2010; San Antonio, TX. http://www.aapainmanage.org/pain_management_news/NEW_newsletter/landingpage/research0310.html. Accessed December 7, 2010.
5. Zagari MJ, Mazonson PD, Longton WC. Pharmacoeconomics of chronic nonmalignant pain. Pharmacoeconomics. 1996;10(4):356-377.
6. Burgoyne DS. Prevalence and economic implications of chronic pain. Manag Care. 2007;16(2 suppl 3):2-4.
7. Hitchcock LS, Ferrell BR, McCaffery M. The experience of chronic nonmalignant pain. J Pain Symptom Manage. 1994;9(5):312-318.
8. American Pain Society. Chronic pain in America: roadblocks to relief, a study conducted by Roper Starch Worldwide for American Academy of Pain Medicine, American Pain Society, and Janssen Pharmaceutica, 1999. http://www.ampainsoc.org/resources/roadblocks/summary2_road.htm. Accessed November 8, 2010.
9. Katz WA, Barkin RL. Dilemmas in chronic/persistent pain management. Am J Ther. 2008;15(3):256-264.
10. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
11. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drugrelated behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444-459.
12. Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain. 1992;8(2):77-85.
13. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23(4):307-315.
14. Michna E, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain. 2007;23(2):173-179.
15. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11(suppl 2):S5-S62.
16. National Drug Intelligence Center, US Department of Justice. Methadone diversion, abuse, and misuse: deaths increasing at alarming rate. Product No. 2007-Q0317-001; November 2007. http://www.justice.gov/ndic/pubs25/25930/25930p.pdf. Accessed November 25, 2010.
17. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996;11(4):203-217.
18. Pergolizzi J, Pappagallo M, Stauffer J, et al; Integrated Drug Compliance Study Group (IDCSG). The role of urine drug testing for patients on opioid therapy. Pain Pract. 2010;10(6):497-507.
19. Heit HA, Gourlay DL. DSM-V and the definitions: time to get it right. Pain Med. 2009;10(5):784-786.
20. Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage. 2003;26(1): 655-667.
21. Goldberg GA, Kim SS, Seifeldin R, Patton MP, Haberman M. Health care costs associated with suboptimal management of persistent pain. Manag Care. 2003;12(8):14-17.
22. Ruetsch CR. Empirical view of opioid dependence. J Manag Care Pharm. 2010;16(suppl 1B):S9-S13.
23. Manchikanti L. Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Pain Physician. 2006;9(4): 287-321.
24. Leider HL, Dhaliwal J, Davis EJ, Kulakodlu M, Buikema AR. Healthcare costs and nonadherence among chronic opioid users. Am J Manag Care. 2011;17(1):32-40.
25. Manchikanti L, Manchukonda R, Pampati V, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9(2):123-129.
26. Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97(4):1097-1102.
27. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9(1):1-39.
28. Jan SA. Patient perspective, complexities, and challenges in managed care. J Manag Care Pharm. 2010;16(suppl 1B):S22-S25.
29. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290(18):2443-2454.
30. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11(6):469-479.
31. Portenoy RK. Acute and chronic pain. In: Ruiz P, Strain E, eds. Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook. 5th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2011;695-720.
32. Manchikanti L, Benyamin R, Datta S, Vallejo R, Smith H. Opioids in chronic noncancer pain. Expert Rev Neurother. 2010;10(5):775-789.
33. Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician. 2008;11(suppl 2):S155-S180.
34. Gilbert JW, Wheeler GR, Mick GE, et al. Urine drug testing in the treatment of chronic noncancer pain in a Kentucky private neuroscience practice: the potential effect of Medicare benefit changes in Kentucky. Pain Physician. 2010;13(2):187-194.
35. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manag. 2004;27(3):260-267.
36. Evans M, Kriger S, Gunn J, Schwilke G. Compliance monitoring and effective risk mitigation strategy. Practical Pain Management. 2010; 10(5):43-46.
37. Hammett-Stabler CA, Webster LR. A Clinical Guide to Urine Drug Testing: Augmenting Pain Management and Enhancing Patient Care. Newark, NJ: UMDNJ-Center for Continuing and Outreach Education; 2008.
38. iCup [package insert]. Norfolk, VA: Instant Technologies; 2005.
39. Buckley NA. Abnormal laboratory results: drug screens. Australian Prescriber. 2001;24(4):90-91.
40. Neafsey P, Ginsberg G, Hattis D, Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev. 2009;12(5-6): 334-361.
41. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349-355.
42. Shulman RW, Özdemir V. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly. Can J Psychiatry 1997;42(1 suppl):4S-9S.
43. Evans M, Kriger S, Gunn J, Schwilke G. Effective monitoring of opiates in chronic pain patients. Practical Pain Management. 2009;9(6):32-33.
44. Centers for Medicare and Medicaid Services. Medicare fee schedules. http://www.cms.gov/ClinicalLabFeeSched/02_clinlab.asp#TopOfPage. Accessed January 4, 2011.